Clinical trial
Double Blind Atorvastatin Amlodipine Study
NCT00159718 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159718 |
|---|---|
| Title | Double Blind Atorvastatin Amlodipine Study |
| Official title | Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease. |
| Acronym | DUAAL |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Angina |
| Intervention type | Drug |
| Interventions | amlodipine, atorvastatin |
| Enrollment | 360 |
| Start date | Jul 1, 2001 |
| Completion | Jan 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 28, 2021 |
| Countries | Croatia, Czechia, Estonia, Hungary, Latvia, Norway, Poland, Romania, Slovakia, South Africa, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: